# MMAF

Source: https://onco.cc/terms/mmaf/  
OnCo record `mmaf` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MMAF is a charged cousin of MMAE that cannot cross membranes, so it kills only the targeted cell and spares neighbours. Eye side effects are characteristic.

## Summary

MMAF, monomethyl auristatin F, is a charged cousin of MMAE that cannot cross cell membranes, so it kills only the cell the antibody targets and spares its neighbours. The charge comes from a C-terminal phenylalanine, which stops the free payload leaving the cell. Used with non-cleavable linkers, in the form known as mafodotin, it produces little Bystander effect (ADC) and less neuropathy than MMAE, but it has a distinctive corneal toxicity seen with Belantamab mafodotin. The payload belongs to the Antibody-drug conjugate (ADC) technology and to the terms Payload (ADC) and Tubulin inhibitor payloads, and it is referenced by the linker term Maleimidocaproyl (mc), non-cleavable, which is its usual partner.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: monomethyl auristatin F; mafodotin payload; monomethyl auristatin F, mafodotin

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Monomethyl_auristatin_F
- Wikipedia: https://en.wikipedia.org/wiki/Monomethyl_auristatin_F

## Connected records

- terms: [Bystander effect (ADC)](https://onco.cc/terms/bystander-effect/), [Maleimidocaproyl (mc), non-cleavable](https://onco.cc/terms/mc-non-cleavable/), [Payload (ADC)](https://onco.cc/terms/payload/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/)

---
JSON: https://onco.cc/api/v1/entities/mmaf.json